Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertolt Kreft

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Chembiochem : a European Journal of Chemical Biology|March 3, 2005
The target discovery processUrsula Egner, Jörn Krätzschmar, Bertolt Kreft, et al.
Cellular Signalling|October 26, 2005
LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domainDaniel Korr, Luisella Toschi, Peter Donner, et al.
Breast Cancer Research and Treatment|March 14, 2013
Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. Comprehensive characterization of an isogenic human mammary epithelial cell model provides evidence for epithelial-mesenchymal transitionUlrike Ulbricht, Anette Sommer, Georg Beckmann, et al.
Molecular Human Reproduction|March 27, 2004
Cyr61, a deregulated gene in endometriosisYvonne Absenger, Holger Hess-Stumpp, Bertolt Kreft, et al.
Cancer Medicine|December 11, 2014
Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cisJulia C Meier, Bernard Haendler, Henrik Seidel, et al.
The Journal of Biological Chemistry|April 1, 2016
Functional and Structural Characterization of Bub3·BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human CellsFlorian Prinz, Vera Puetter, Simon J Holton, et al.
Molecular Cancer Therapeutics|April 10, 2014
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effectSven Golfier, Charlotte Kopitz, Antje Kahnert, et al.
Journal of Medicinal Chemistry|September 27, 2024
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against CancerJeffrey Mowat, Rafael Carretero, Gabriele Leder, et al.
Cancer Immunology Research|April 22, 2020
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)Julia Huetter, Uwe Gritzan, Ilona Gutcher, et al.
Molecular Cancer Therapeutics|February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor ActivityAntje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Chembiochem : a European Journal of Chemical Biology|March 3, 2005
The target discovery processUrsula Egner, Jörn Krätzschmar, Bertolt Kreft, et al.
Cellular Signalling|October 26, 2005
LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domainDaniel Korr, Luisella Toschi, Peter Donner, et al.
Breast Cancer Research and Treatment|March 14, 2013
Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. Comprehensive characterization of an isogenic human mammary epithelial cell model provides evidence for epithelial-mesenchymal transitionUlrike Ulbricht, Anette Sommer, Georg Beckmann, et al.
Molecular Human Reproduction|March 27, 2004
Cyr61, a deregulated gene in endometriosisYvonne Absenger, Holger Hess-Stumpp, Bertolt Kreft, et al.
Cancer Medicine|December 11, 2014
Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cisJulia C Meier, Bernard Haendler, Henrik Seidel, et al.
The Journal of Biological Chemistry|April 1, 2016
Functional and Structural Characterization of Bub3·BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human CellsFlorian Prinz, Vera Puetter, Simon J Holton, et al.
Molecular Cancer Therapeutics|April 10, 2014
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effectSven Golfier, Charlotte Kopitz, Antje Kahnert, et al.
Journal of Medicinal Chemistry|September 27, 2024
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against CancerJeffrey Mowat, Rafael Carretero, Gabriele Leder, et al.
Cancer Immunology Research|April 22, 2020
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)Julia Huetter, Uwe Gritzan, Ilona Gutcher, et al.
Molecular Cancer Therapeutics|February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor ActivityAntje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Pageof 2